Market Intel: How 3D Printing Can Enhance And Expand Medtech Opportunities
Executive Summary
3D printing has been hailed as a potentially game-changing technology for different industries. Biomedical applications, in particular, have garnered much attention when patients were able to receive 3D-printed, customized, lifesaving medical interventions. But aside from these niche markets for personalized medical devices, can 3D printing ever become mainstream in health care? This article, a guest column from leaders at the Boston Consulting Group, explores what the benefits of 3D-printed devices are and how they are driving the uptake of this technology. It also assesses how fast this adoption is happening and evaluates how – and in which biomedical applications and device markets – 3D printing could best enhance products and allow medtech manufacturers to grow their business.
You may also be interested in...
Stryker Makes Big Investment In Spine Surgery With $1.4Bn K2M Acquisition
The orthopedics giant will pay $27.50 per share for the Leesburg, Va., company, representing a 27% premium over K2M's average closing price over the last 90 days. The terms of the deal also call for K2M CEO to take over as president of Stryker's Spine business, displacing current president Bradley Paddock.
Market Intel: Nanorobots, Digital Tracking, Dose Printing: Innovative Drug Delivery Systems Will Make Precise Drug Dosing A Reality
Precision medicine delivered by novel drug delivery systems, ranging from sensors to dose printers, could eventually revolutionize the pharmaceutical industry. Although many of these technologies are years away from commercialization, their ability to provide exact dosing with slow sustained release and more targeted therapy should improve patient compliance and outcomes.
3D-Printing Final Guidance Clarifies Manufacturing Practice Expectations
A year and a half after FDA issued a draft guidance to help makers of devices that rely on additive manufacturing, the agency has finalized the document in its bid to get ahead of the technology. The final guidance makes minor clarifications, but for the most is identical to the draft.